Was an intensely hyped Nature paper connected to the subsequent knighthood for one of the authors just two days after publication? It’s hard to imagine there isn’t a connection and such a link is bad news for biomedical science. Professor Doug Turnbull and fellow UK authors published a Nature paper a few days ago that reinforced a […]
Hyped Nature paper & author knighthood 2 days later raise red flags Read More »
Can stem cells mend a broken heart via cardiac regenerative medicine? The idea of the use of stem cells and regenerative medicine strategies for heart disease has taken us on a roller coaster ride over the years. There are many controversial questions still such as whether the adult heart has meaningful populations of endogenous stem
Stem Cells on Valentine’s Day: Cardiac Regenerative Medicine Read More »
Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind
ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »
California stem cell biotech, StemCells, Inc. ($STEM), has really struggled for years and its stock is now flatlining raising the question: can it cheat death? Will 2016 be the year that STEM turns things around? So far this year hasn’t started off that well. You can see the graph at right from today on the
Can StemCells Inc. Cheat Death? Read More »
Forget retracting a paper, could Paolo Macchiarini try to get a retraction of Vanity Fair piece on his wild personal life an CV? Macchiarini is one of the more well-known stem cell and regenerative medicine researchers, and not always related to good news. You can see read posts I’ve done on him on this blog including
Vanity Fair Dissects Stem Cell Surgeon Macchiarini in Exposé Read More »
What were the top 10 stem cell stories of the year? What were the biggest news and science headlines in the stem cell field in 2015, whether good or bad? Below are mine. What are your top 10 stem cell stories of the past year? Let us know in the comments. Organoids explode. Stem cell-based
Key stem cell stories of the year 2015 Read More »
GOP members of Congress want a ban on CRISPR of human embryos. They are moving to block genetic modification of human embryos using the new CRISPR gene editing technology. The new proposed spending bill part way through the approval process with the nugget of good news of a possible NIH spending boost after many years
GOP Congress seeks ban on CRISPR of human embryos Read More »
Congratulations to Lorenz Studer as a MacArthur Fellow. The annual selection of MacArthur Fellows highlights creative leaders in a variety of fields. The fellows receive $625,000 with no strings attached. Stem cell biologists have been selected on a regular basis over the years as MacArthur Fellows including Kevin Eggan (2006), Sally Temple (2008), and Yukiko
Lorenz Studer named 2015 MacArthur Fellow for stem cell work Read More »
I recently chatted with Sean Morrison, current President of ISSCR, on his goals for the Society, where the stem cell field stands today, top challenges, and the future. 2020 update: read my new interview with Sean on cell therapies for COVID-19. What are your goals for your tenure as President of ISSCR? SM: ISSCR is the
ISSCR President Sean Morrison on challenges and future of stem cell field Read More »
To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those
Tale of 7 stem cell biotech stock woes Read More »